Cargando…

肿瘤患者新冠疫苗接种:临床研究进展与初步临床推荐

The pandemic of coronavirus disease 2019 (COVID-19) has had a serious impact on global health. COVID-19 vaccines may be one of the most effective measure to end the pandemic. High infection risk and higher serious incident and mortality rates have been shown in cancer patients with COVID-19. Therefo...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246390/
https://www.ncbi.nlm.nih.gov/pubmed/34024060
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.18
_version_ 1783716303317499904
collection PubMed
description The pandemic of coronavirus disease 2019 (COVID-19) has had a serious impact on global health. COVID-19 vaccines may be one of the most effective measure to end the pandemic. High infection risk and higher serious incident and mortality rates have been shown in cancer patients with COVID-19. Therefore, cancer patients should be the priority group for COVID-19 prevention. Until now, data of COVID-19 vaccination for cancer patients is lacking. We review the interim data of safety and immune-efficacy of COVID-19 vaccination in cancer patients based on the latest studies. Due to the complicated immune systems of cancer patients caused by the malignancy and anticancer treatments, we proposed preliminary specific COVID-19 vaccination recommendations for cancer patients with different anticancer treatments and at different stages of the disease. Preventing COVID-19 with vaccinations for cancer patients is crucial, and we call for more large-scale clinical trials and real-world studies, for further COVID-19 vaccination recommendations development.
format Online
Article
Text
id pubmed-8246390
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-82463902021-07-13 肿瘤患者新冠疫苗接种:临床研究进展与初步临床推荐 Zhongguo Fei Ai Za Zhi 专家述评 The pandemic of coronavirus disease 2019 (COVID-19) has had a serious impact on global health. COVID-19 vaccines may be one of the most effective measure to end the pandemic. High infection risk and higher serious incident and mortality rates have been shown in cancer patients with COVID-19. Therefore, cancer patients should be the priority group for COVID-19 prevention. Until now, data of COVID-19 vaccination for cancer patients is lacking. We review the interim data of safety and immune-efficacy of COVID-19 vaccination in cancer patients based on the latest studies. Due to the complicated immune systems of cancer patients caused by the malignancy and anticancer treatments, we proposed preliminary specific COVID-19 vaccination recommendations for cancer patients with different anticancer treatments and at different stages of the disease. Preventing COVID-19 with vaccinations for cancer patients is crucial, and we call for more large-scale clinical trials and real-world studies, for further COVID-19 vaccination recommendations development. 中国肺癌杂志编辑部 2021-06-20 /pmc/articles/PMC8246390/ /pubmed/34024060 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.18 Text en 版权所有©《中国肺癌杂志》编辑部2021 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 专家述评
肿瘤患者新冠疫苗接种:临床研究进展与初步临床推荐
title 肿瘤患者新冠疫苗接种:临床研究进展与初步临床推荐
title_full 肿瘤患者新冠疫苗接种:临床研究进展与初步临床推荐
title_fullStr 肿瘤患者新冠疫苗接种:临床研究进展与初步临床推荐
title_full_unstemmed 肿瘤患者新冠疫苗接种:临床研究进展与初步临床推荐
title_short 肿瘤患者新冠疫苗接种:临床研究进展与初步临床推荐
title_sort 肿瘤患者新冠疫苗接种:临床研究进展与初步临床推荐
topic 专家述评
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246390/
https://www.ncbi.nlm.nih.gov/pubmed/34024060
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.18
work_keys_str_mv AT zhǒngliúhuànzhěxīnguānyìmiáojiēzhǒnglínchuángyánjiūjìnzhǎnyǔchūbùlínchuángtuījiàn
AT zhǒngliúhuànzhěxīnguānyìmiáojiēzhǒnglínchuángyánjiūjìnzhǎnyǔchūbùlínchuángtuījiàn
AT zhǒngliúhuànzhěxīnguānyìmiáojiēzhǒnglínchuángyánjiūjìnzhǎnyǔchūbùlínchuángtuījiàn
AT zhǒngliúhuànzhěxīnguānyìmiáojiēzhǒnglínchuángyánjiūjìnzhǎnyǔchūbùlínchuángtuījiàn
AT zhǒngliúhuànzhěxīnguānyìmiáojiēzhǒnglínchuángyánjiūjìnzhǎnyǔchūbùlínchuángtuījiàn
AT zhǒngliúhuànzhěxīnguānyìmiáojiēzhǒnglínchuángyánjiūjìnzhǎnyǔchūbùlínchuángtuījiàn
AT zhǒngliúhuànzhěxīnguānyìmiáojiēzhǒnglínchuángyánjiūjìnzhǎnyǔchūbùlínchuángtuījiàn